PIK3CA and breast cancer: The LORELEI trial was a phase II, multicenter, randomized, double-blind, placebo-controlled study of letrozole in association with taselisib versus letrozole, with placebo for early HR+/HER2− BC in the neoadjuvant setting (n = 334), 46% of them displaying PIK3CA mutations.